Details of the Drug

General Information of Drug (ID: DM8HLO5)

Drug Name
Canakinumab
Synonyms Ilaris (TN)
Indication
Disease Entry ICD 11 Status REF
Cryopyrin-associated periodic syndromes 4A60.1 Approved [1], [2]
Rheumatoid arthritis FA20 Approved [1], [2]
Urticaria EB00-EB05 Phase 2 [1], [2]
Vasculitis 4A44 Phase 2 [1], [2]
Drug Type
Antibody
Sequence
>sequence 1
QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYY
ADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK
>sequence 2
QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYY
ADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPS
RFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Bioavailability
The bioavailability of drug is estimated to be 70% [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 26 days [4]
Vd
The volume of distribution (Vd) of drug is 6.01 L [5]
Cross-matching ID
DrugBank ID
DB06168
TTD ID
D0TD2G

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-1 beta (IL1B) TTRYK0X IL1B_HUMAN Not Available [2], [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cryopyrin-associated periodic syndromes
ICD Disease Classification 4A60.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-1 beta (IL1B) DTT IL1B 3.94E-01 0.07 0.26
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Canakinumab
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Canakinumab and Golimumab. Rheumatoid arthritis [FA20] [17]
Coadministration of a Drug Treating the Disease Different from Canakinumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Additive immunosuppressive effects by the combination of Canakinumab and Midostaurin. Acute myeloid leukaemia [2A60] [18]
Oliceridine DM6MDCF Moderate Altered metabolism of Canakinumab due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [19]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Canakinumab and Siltuximab. Anemia [3A00-3A9Z] [18]
Dupilumab DMOAD2Y Moderate Additive immunosuppressive effects by the combination of Canakinumab and Dupilumab. Atopic eczema [EA80] [18]
Eribulin DM1DX4Q Moderate Additive immunosuppressive effects by the combination of Canakinumab and Eribulin. Breast cancer [2C60-2C6Y] [18]
Talazoparib DM1KS78 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Talazoparib. Breast cancer [2C60-2C6Y] [18]
LY2835219 DM93VBZ Moderate Additive immunosuppressive effects by the combination of Canakinumab and LY2835219. Breast cancer [2C60-2C6Y] [18]
Pralatrexate DMAO80I Moderate Additive immunosuppressive effects by the combination of Canakinumab and Pralatrexate. Breast cancer [2C60-2C6Y] [18]
Palbociclib DMD7L94 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Palbociclib. Breast cancer [2C60-2C6Y] [18]
Cabazitaxel DMPAZHC Moderate Additive immunosuppressive effects by the combination of Canakinumab and Cabazitaxel. Breast cancer [2C60-2C6Y] [18]
Bosutinib DMTI8YE Moderate Additive immunosuppressive effects by the combination of Canakinumab and Bosutinib. Breast cancer [2C60-2C6Y] [18]
Aflibercept DMT3D5I Moderate Additive immunosuppressive effects by the combination of Canakinumab and Aflibercept. Colorectal cancer [2B91] [18]
Levonorgestrel DM1DP7T Moderate Altered metabolism of Canakinumab due to Levonorgestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [19]
Rivaroxaban DMQMBZ1 Moderate Altered metabolism of Canakinumab due to Rivaroxaban alters the formation of CYP450 enzymes. Deep vein thrombosis [BD71] [19]
Polatuzumab vedotin DMF6Y0L Moderate Additive immunosuppressive effects by the combination of Canakinumab and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [18]
Axicabtagene ciloleucel DMYHN59 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [18]
Oestradiol valerate and dienogest DMZK0FQ Moderate Altered metabolism of Canakinumab due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. Endometriosis [GA10] [20]
Bay 80-6946 DMLOS5R Moderate Additive immunosuppressive effects by the combination of Canakinumab and Bay 80-6946. Follicular lymphoma [2A80] [18]
Avapritinib DMK2GZX Moderate Additive immunosuppressive effects by the combination of Canakinumab and Avapritinib. Gastrointestinal stromal tumour [2B5B] [18]
177Lu-DOTATATE DMT8GVU Moderate Additive immunosuppressive effects by the combination of Canakinumab and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [18]
Brentuximab vedotin DMWLC57 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Brentuximab vedotin. Hodgkin lymphoma [2B30] [18]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Canakinumab and Teriflunomide. Hyper-lipoproteinaemia [5C80] [21]
Levamlodipine DM92S6N Moderate Altered metabolism of Canakinumab due to Levamlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [19]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Canakinumab and Denosumab. Low bone mass disorder [FB83] [22]
Brigatinib DM7W94S Moderate Additive immunosuppressive effects by the combination of Canakinumab and Brigatinib. Lung cancer [2C25] [18]
Lurbinectedin DMEFRTZ Moderate Additive immunosuppressive effects by the combination of Canakinumab and Lurbinectedin. Lung cancer [2C25] [19]
Osimertinib DMRJLAT Moderate Additive immunosuppressive effects by the combination of Canakinumab and Osimertinib. Lung cancer [2C25] [18]
Belimumab DM3OBQF Moderate Additive immunosuppressive effects by the combination of Canakinumab and Belimumab. Lupus erythematosus [4A40] [18]
Ofatumumab DM295PR Moderate Additive immunosuppressive effects by the combination of Canakinumab and Ofatumumab. Mature B-cell leukaemia [2A82] [18]
Obinutuzumab DM3BVAE Moderate Additive immunosuppressive effects by the combination of Canakinumab and Obinutuzumab. Mature B-cell leukaemia [2A82] [18]
Idelalisib DM602WT Moderate Additive immunosuppressive effects by the combination of Canakinumab and Idelalisib. Mature B-cell leukaemia [2A82] [18]
GDC-0199 DMH0QKA Moderate Additive immunosuppressive effects by the combination of Canakinumab and GDC-0199. Mature B-cell leukaemia [2A82] [18]
IPI-145 DMWA24P Moderate Additive immunosuppressive effects by the combination of Canakinumab and IPI-145. Mature B-cell leukaemia [2A82] [18]
Acalabrutinib DM7GCVW Moderate Additive immunosuppressive effects by the combination of Canakinumab and Acalabrutinib. Mature B-cell lymphoma [2A85] [18]
Blinatumomab DMGECIJ Moderate Additive immunosuppressive effects by the combination of Canakinumab and Blinatumomab. Mature B-cell lymphoma [2A85] [18]
Ibrutinib DMHZCPO Moderate Additive immunosuppressive effects by the combination of Canakinumab and Ibrutinib. Mature B-cell lymphoma [2A85] [18]
Tisagenlecleucel DMM9BJD Moderate Additive immunosuppressive effects by the combination of Canakinumab and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [18]
Ponatinib DMYGJQO Moderate Additive immunosuppressive effects by the combination of Canakinumab and Ponatinib. Mature B-cell lymphoma [2A85] [18]
Carfilzomib DM48K0X Moderate Additive immunosuppressive effects by the combination of Canakinumab and Carfilzomib. Multiple myeloma [2A83] [18]
Panobinostat DM58WKG Moderate Additive immunosuppressive effects by the combination of Canakinumab and Panobinostat. Multiple myeloma [2A83] [18]
Selinexor DMBD4K3 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Selinexor. Multiple myeloma [2A83] [18]
Belantamab mafodotin DMBT3AI Moderate Additive immunosuppressive effects by the combination of Canakinumab and Belantamab mafodotin. Multiple myeloma [2A83] [18]
Elotuzumab DMEYHG9 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Elotuzumab. Multiple myeloma [2A83] [18]
Daratumumab DMKCIUZ Moderate Additive immunosuppressive effects by the combination of Canakinumab and Daratumumab. Multiple myeloma [2A83] [18]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Canakinumab and Tecfidera. Multiple sclerosis [8A40] [18]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Canakinumab and Siponimod. Multiple sclerosis [8A40] [17]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Canakinumab and Fingolimod. Multiple sclerosis [8A40] [23]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Canakinumab and Ocrelizumab. Multiple sclerosis [8A40] [18]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Canakinumab and Ozanimod. Multiple sclerosis [8A40] [19]
Deflazacort DMV0RNS Moderate Additive immunosuppressive effects by the combination of Canakinumab and Deflazacort. Muscular dystrophy [8C70] [18]
Romidepsin DMT5GNL Moderate Additive immunosuppressive effects by the combination of Canakinumab and Romidepsin. Mycosis fungoides [2B01] [18]
Ruxolitinib DM7Q98D Moderate Additive immunosuppressive effects by the combination of Canakinumab and Ruxolitinib. Myeloproliferative neoplasm [2A20] [18]
Inebilizumab DMI0RHA Moderate Additive immunosuppressive effects by the combination of Canakinumab and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [18]
Atezolizumab DMMF8U0 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Atezolizumab. Non-small cell lung cancer [2C25] [18]
Olaparib DM8QB1D Moderate Additive immunosuppressive effects by the combination of Canakinumab and Olaparib. Ovarian cancer [2C73] [18]
Rucaparib DM9PVX8 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Rucaparib. Ovarian cancer [2C73] [18]
MK-4827 DMLYGH4 Moderate Additive immunosuppressive effects by the combination of Canakinumab and MK-4827. Ovarian cancer [2C73] [18]
Brodalumab DMASDQ6 Moderate Additive immunosuppressive effects by the combination of Canakinumab and Brodalumab. Psoriasis [EA90] [18]
Tildrakizumab DMLW9HG Moderate Additive immunosuppressive effects by the combination of Canakinumab and Tildrakizumab. Psoriasis [EA90] [18]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Canakinumab and Risankizumab. Psoriasis [EA90] [18]
Ixekizumab DMXW92T Moderate Additive immunosuppressive effects by the combination of Canakinumab and Ixekizumab. Psoriasis [EA90] [18]
Temsirolimus DMS104F Moderate Additive immunosuppressive effects by the combination of Canakinumab and Temsirolimus. Renal cell carcinoma [2C90] [19]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Canakinumab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [24]
Mogamulizumab DMISH0Z Moderate Additive immunosuppressive effects by the combination of Canakinumab and Mogamulizumab. Sezary syndrome [2B02] [18]
LEE011 DMMX75K Moderate Additive immunosuppressive effects by the combination of Canakinumab and LEE011. Solid tumour/cancer [2A00-2F9Z] [18]
Pomalidomide DMTGBAX Moderate Additive immunosuppressive effects by the combination of Canakinumab and Pomalidomide. Systemic sclerosis [4A42] [18]
Plicamycin DM7C8YV Moderate Additive immunosuppressive effects by the combination of Canakinumab and Plicamycin. Testicular cancer [2C80] [18]
Apixaban DM89JLN Moderate Altered metabolism of Canakinumab due to Apixaban alters the formation of CYP450 enzymes. Thrombosis [DB61-GB90] [19]
Belatacept DMXLYQF Moderate Additive immunosuppressive effects by the combination of Canakinumab and Belatacept. Transplant rejection [NE84] [18]
Durvalumab DM4PVDY Moderate Additive immunosuppressive effects by the combination of Canakinumab and Durvalumab. Ureteral cancer [2C92] [18]
⏷ Show the Full List of 70 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6773).
2 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
7 Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98.
8 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
9 Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41.
10 Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86.
11 Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
12 Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
15 A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
17 Cerner Multum, Inc. "Australian Product Information.".
18 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
21 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
22 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
23 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
24 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]